FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

FLASCO Prior Authorization Webinar

On April 17th, FLASCO’s Administrator Network hosted a webinar to discuss the challenges faced by practices when dealing with Prior Authorizations. We were joined by Risë Cleland, who presented Practical Strategies: The Challenge of Prior Authorization Burdens . Following Risë’s presentation, a panel representing different types of oncology practices in Florida, provided further insight on the topic. ...

FLASCO Administrator Network Patient Support Resources Webinar

  On January 12, 2017, the FLASCO Administrator Network hosted its first webinar. The topic was Patient Support Resources, and it featured experts from community oncology  and hospital settings, who shared their tips, helpful hints, and tools of the trade regarding assistance programs and resources available for cancer patients. Congratulations to Maggie Wiegandt, MBA and Gail...

CMS Finalizes the New Medicare Quality Payment Program  – MACRA

On October 14, HHS finalized its policy implementing the Merit-Based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (APM) incentive payment provisions in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), collectively referred to as the Quality Payment Program. Accompanying the announcement is a new Quality Payment Program website, which will explain the...

FLASCO Prior Authorization Webinar

On April 17th, FLASCO’s Administrator Network hosted a webinar to discuss the challenges faced by practices when dealing with Prior Authorizations. We were joined by Risë Cleland, who presented Practical Strategies: The Challenge of Prior Authorization Burdens . Following Risë’s presentation, a panel representing different types of oncology practices in Florida, provided further insight on the topic. ...

Blue Cross Blue Shield Recognizes Florida Cancer Specialists & Research Institute for Quality in Value-Based Cancer Care

Brought to you by a 100% FLASCO Membership Partner Fort Myers, Florida, April 19th, 2018… Florida Cancer Specialists & Research Institute (FCS) has been recognized by Blue Cross Blue Shield as a Blue Distinction® Center for Cancer Care. FCS is the only community hematology and oncology practice in the state of Florida to be awarded this recognition. By...

astrazeneca

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

1st-line use of Tagrisso offers potential new standard of care Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care   AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)...

FDA approves fostamatinib tablets for ITP

On April 17, 2018, the Food and Drug Administration approved fostamatinib disodium hexahydrate tablets (TAVALISSE, Rigel Pharmaceuticals, Inc.) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Approval was based on two identical, double-blind, placebo-controlled trials, FIT-1 (NCT02076399) and FIT-2 (NCT02076412)...

Who’s Online

Profile picture of FLASCO